Grace H. Attrill

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypes.

Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypes.

Journal: Genome medicine
Published: May 22, 2025

CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses.

CD4+ T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses.

Journal: Science immunology
Published: January 19, 2024

Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.

Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.

Journal: Nature communications
Published: April 16, 2023

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.

Journal: Journal for immunotherapy of cancer
Published: August 24, 2022

Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.

Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.

Journal: Frontiers in immunology
Published: June 28, 2022

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.

Journal: Journal for immunotherapy of cancer
Published: May 04, 2022

Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.

Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.

Journal: Nature cancer
Published: December 11, 2020

Publisher Correction: Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.

Publisher Correction: Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence.

Journal: Nature cancer
Published: April 01, 2020

The tumour immune landscape and its implications in cutaneous melanoma.

The tumour immune landscape and its implications in cutaneous melanoma.

Journal: Pigment cell & melanoma research
Published: March 20, 2020

Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model.

Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model.

Journal: PloS one
Published: November 19, 2019

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.

Journal: Oncoimmunology
Published: March 22, 2018
Showing 1-11 of 11

Last Updated: 09/26/2026